Gavi, the Vaccine Alliance has launched INFUSE 2.0, an innovation scaling hub to accelerate immunisation systems upgrades for the world’s most in-need countries, and worth $500million, reports ITREALMS.
By 2030, INFUSE 2.0 expects to secure at least US$ 500 million in private investment to promote access to new and under-used vaccines and immunisation innovations in the fight against deadly and debilitating infectious diseases.
“The pandemic has rolled back years of progress improving vaccine coverage in the world’s most vulnerable countries,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance.
“With millions more children now at risk of deadly, preventable diseases, we need to ensure the most promising, most scalable innovations reach the countries that need them, urgently. INFUSE 2.0 can do just that, bringing together investors looking for impact with entrepreneurs who can deliver it to help protect children across the world.”
The new initiative builds on Innovation for Uptake, Scale and Equity in Immunisation (INFUSE) 1.0, launched in 2016, which has cultivated a community of start-up innovators overcoming vaccine delivery challenges. Initial investments in INFUSE totalled more than US$ 60 million, leading to more than US$ 200 million in follow-on funding for global health innovators.
The new initiative builds on Innovation for Uptake, Scale and Equity in Immunisation (INFUSE) 1.0, launched in 2016, which has cultivated a community of start-up innovators overcoming vaccine delivery challenges. Initial investments in INFUSE totalled more than US$ 60 million, leading to more than US$ 200 million in follow-on funding for global health innovators.
No comments:
Post a Comment